Another clinical trial demonstrates that SPECT/CT assessment of PD-L1 expression in NSCLC patients can present and image characteristics correlating with PD-L1 immunohistochemistry well by using 99mTc-NM-01-labeled anti-PD-L1 single-domain antibody, which is safe and has favorable biodistribution (66). Here, CD274 is linked to non-small cell lung carcinoma.